EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, Hee Sun Cho, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Heechul Nam, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Do Seon Song und 7 weitere

Frontiers in Oncology · 28.02.2024 · 14

DOI: 10.3389/fonc.2024.1372007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.02.2024. Verfasst von Ji Won Han und 18 weiteren Autor:innen. Beteiligte Einrichtung: The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atezolizumab+bevacizumab (AB) and lenvatinib have been proposed as first-line treatment options for patients with advanced hepatocellular carcinoma (HCC), but comparative efficacy and associated factors are controversial. Materials and methods This real-world multicenter study analysed patients with HCC who received AB (n=169) or lenvatinib (n=177).

Results

First, 1:1 propensity score matching (PSM) was performed, resulting in 141 patients in both the AB and lenvatinib groups. After PSM, overall survival (OS) was better in the AB group than in the lenvatinib group [hazard ratio (HR)=0.642, P=0.009], but progression-free survival (PFS) did not vary between the two groups (HR=0.817, P=0.132). Objective response rate (ORR) was also similar between AB and lenvatinib (34.8% vs. 30.8%, P=0.581). In a subgroup of patients with objective responses (OR, n=78), OS (HR=0.364, P=0.012) and PFS (HR=0.536, P=0.019) were better in the AB group (n=41) than in the lenvatinib group (n=37). Time-to-progression from time of OR was also better in the AB group (HR=0.465, P=0.012). Importantly, residual liver function was a significant factor related to OS in both treatments. Child-Pugh score following cessation of the respective treatments was better in the AB group (n=105) than in the lenvatinib group (n=126) (median 6 versus 7, P=0.008), and proportion of salvage treatment was also higher in the AB group (52.4% versus 38.9%, P=0.047). When we adjusted for residual liver function or salvage treatment, there was no difference in OS between the two treatments.

Conclusion

Our study suggests that residual liver function and subsequent salvage treatments are major determinants of clinical outcomes in patients treated with AB and lenvatinib; these factors should be considered in future comparative studies.

Schlagwörter

Stichwörter der Autor:innen

HCCatezolizumab plus bevacizumablenvatinibresidual liver functionsurvival

Autor:innen und Institutionen

  • The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Eunpyeong St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Republic of Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Han, J. W., Sung, P. S., Yoo, J. S., Cho, H. S., Lee, S. K., Yang, H., Kim, J. H., Nam, H., Lee, H. L., Kim, H. Y., Lee, S. W., Song, D. S., Song, M. J., Kwon, J. H., Kim, C. W., Bae, S. H., Jang, J. W., Choi, J. Y., & Yoon, S. K. (2024). Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1372007

Vancouver

Han JW, Sung PS, Yoo JS, Cho HS, Lee SK, Yang H, et al. Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1372007

BibTeX
@article{Han2024,
  author = {Han, Ji Won and Sung, Pil Soo and Yoo, Jae-Sung and Cho, Hee Sun and Lee, Soon Kyu and Yang, Hyun and Kim, Ji Hoon and Nam, Heechul and Lee, Hae Lim and Kim, Hee Yeon and Lee, Sung Won and Song, Do Seon and Song, Myeong Jun and Kwon, Jung Hyun and Kim, Chang Wook and Bae, Si Hyun and Jang, Jeong Won and Choi, Jong Young and Yoon, Seung Kew},
  title = {Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1372007}
}
Kostenlos starten →